TNBC lines were selected for these studies primarily because no effective targeted therapeutic is yet available for this class of breast cancers and because we wanted to evaluate AHR signaling in the absence of its well-established interactions with the estrogen receptor [41]. Here, AHR is linked to breast cancer.